[Form 3] Vera Therapeutics, Inc. Initial Statement of Beneficial Ownership

Vera Therapeutics’ Chief Commercial Officer, Skelton Laurence Matthew, has filed an initial ownership report showing equity-based incentives in the company.

Rhea-AI Filing Summary

Vera Therapeutics’ Chief Commercial Officer, Skelton Laurence Matthew, has filed an initial ownership report showing equity-based incentives in the company. He holds 30,000 and 15,800 shares of Class A Common Stock underlying restricted stock units that vest in tranches from November 2026 through February 2029, subject to continued service.

He also holds stock options for 60,000 shares at an exercise price of $41.75 expiring on 10/01/2034 and 31,500 shares at $29.18 expiring on 02/17/2035. These options vest monthly over time, following initial partial vesting completed in January 2026.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Skelton Laurence Matthew

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 91,500 contracts (Direct); Class A Common Stock — 45,800 shares (Direct)

Footnotes (4)

1. F1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs"). One-fourth of the RSUs vested on November 20, 2025, and the remaining three-fourths will vest in equal installments on each of November 20, 2026, 2027 and 2028, subject to the Reporting Person's continuous service through each vesting date.
2. F2. Represents the number of shares of Class A Common Stock underlying the RSUs. One-fourth of the RSUs vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date.
3. F3. One-third of the shares subject to the stock option vested through January 30, 2026, and 1/48 of the shares vest on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.
4. F4. 11/48 of the shares subject to the stock option vested through January 18, 2026 and 1/48 of the shares vest on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Skelton Laurence Matthew

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/20/2026

3. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock	30,000(1)	D
Class A Common Stock	15,800(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(3)	10/01/2034	Class A Common Stock	60,000	$41.75	D
Stock Option (right to buy)	(4)	02/17/2035	Class A Common Stock	31,500	$29.18	D

Explanation of Responses:

1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs"). One-fourth of the RSUs vested on November 20, 2025, and the remaining three-fourths will vest in equal installments on each of November 20, 2026, 2027 and 2028, subject to the Reporting Person's continuous service through each vesting date.

2. Represents the number of shares of Class A Common Stock underlying the RSUs. One-fourth of the RSUs vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date.

3. One-third of the shares subject to the stock option vested through January 30, 2026, and 1/48 of the shares vest on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

4. 11/48 of the shares subject to the stock option vested through January 18, 2026 and 1/48 of the shares vest on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

Exhibit List Exhibit 24 - Power of Attorney No securities are beneficially owned.

	/s/ Joseph Young, attorney-in-fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.